News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
To create leading company developing medicines targeting metalloenzymes
Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
Subscribe To Our Newsletter & Stay Updated
